Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Efstathiou

Showing results (251-260 of 273) with videos related to

Pageof 28
Sort By:
JAMA Oncology|February 11, 2021
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical TrialFelix Y Feng, Huei-Chung Huang, Daniel E Spratt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
Molecular Characterization of Neuroendocrine-like Bladder CancerJosé Batista da Costa, Ewan A Gibb, Trinity J Bivalacqua, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
Science (New York, N.Y.)|June 16, 2018
A dust-enshrouded tidal disruption event with a resolved radio jet in a galaxy mergerS Mattila, M Pérez-Torres, A Efstathiou, et al.
European Urology Oncology|April 19, 2024
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712Zaker Rana, Sophia C Kamran, Amol C Shetty, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
JAMA Oncology|March 28, 2020
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate CancerRobert T Dess, Yilun Sun, William C Jackson, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Pageof 28

Showing results (251-260 of 273) with videos related to

Sort By:
Pageof 28
JAMA Oncology|February 11, 2021
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical TrialFelix Y Feng, Huei-Chung Huang, Daniel E Spratt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
Molecular Characterization of Neuroendocrine-like Bladder CancerJosé Batista da Costa, Ewan A Gibb, Trinity J Bivalacqua, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
Science (New York, N.Y.)|June 16, 2018
A dust-enshrouded tidal disruption event with a resolved radio jet in a galaxy mergerS Mattila, M Pérez-Torres, A Efstathiou, et al.
European Urology Oncology|April 19, 2024
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712Zaker Rana, Sophia C Kamran, Amol C Shetty, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
JAMA Oncology|March 28, 2020
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate CancerRobert T Dess, Yilun Sun, William C Jackson, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Pageof 28